期刊文献+

二茂铁修饰的Aβ抑制剂的合成与性质 被引量:4

Synthesis and properties of Ferrocene-modified Aβ inhibitor
下载PDF
导出
摘要 抑制β-淀粉样蛋白(Aβ)的纤维化是治疗阿尔茨海默病的有效途径之一,其中NH2-Leu-Pro-Phe-Phe-Asp-OH(iAβ5)是效果较好、研究较多的寡肽类Aβ抑制剂。将二茂铁基团与iAβ5结合,得到了Fc-Leu-Pro-Phe-Phe-Asp(OMe)-OMe(Fc-iAβ5)化合物。即以二茂铁甲酸和各种氨基酸为原料,以苯并三唑-1-四甲基六氟磷酸酯(HBTU)及1-羟基苯并三唑(HOBt)为耦合剂,采用液相合成法,合成了Fc-Leu-Pro-Phe-Phe-Asp(OMe)-OMe。利用IR,NMR和MS确证了Fc-iAβ5的结构。用ThT荧光探针法检测了Fc-iAβ5对β-淀粉样蛋白Aβ1-42纤维化的抑制作用。实验结果表明,Fc-iAβ5能有效地抑制Aβ1-42纤维的形成,并且能有效地分解已形成的Aβ1-42纤维,其抑制效果优于五肽iAβ5。 The aggregation of β-amyloid peptide (Aβ) plays a key role in Alzheimer's disease. NH2-Leu- Pro-Phe-Phe-Asp-OH (iAβ5), a typical oligopeptide inhibitor for β-amyloid peptide (Aβ), was modified by ferrocenyl moiety in the investigation. Fc-Leu-Pro-Phe-Phe-Asp(OMe)-OMe (Fc-iAβ5,Fc:ferrocene) was synthesized from ferrocene monocarboxylic acid and amino acids in solution using HBTU and HOBt as coupling reagents. The ferrocenyl peptide, Fc-Leu-Pro-Phe-Phe-Asp(OMe)-OMe (Fc-iAβ5), was characterized by IR, NMR and MS. The inhibitory properties of Fc-iAβ for the aggregation of Aβ1-42 were investigated by thioflavin T (ThT) fluorescence spectroscopy in vitro. The experimental results showed that ferrocene attached iAβ5 inhibits Aβ1-42 fibrillogenesis more strongly than iAβ5 itself. Moreover, Fc-iAβ5 is able to partially disaggregate performed fibrils.
出处 《中国科技论文在线》 CAS 2009年第6期431-435,共5页
基金 国家自然科学基金(20676153 20876179)
关键词 药物合成 Aβ抑制剂 二茂铁衍生肽 多肽合成 阿尔茨海默病 sysnthesis of pharmacies Aβ inhibitor ferrocenyl peptide peptide synthesis Alzheimer's disease
  • 相关文献

参考文献2

二级参考文献44

  • 1颜承农,张华新,刘义,梅平,李克华,童金强.百草枯与牛血清白蛋白结合作用的荧光光谱[J].化学学报,2005,63(18):1727-1732. 被引量:83
  • 2Santin, M.; Motta, A.; Freddi, G.; Cannas, M. J. Mater. Res.1999, 46, 382.
  • 3Langer, R.; Vacanti, J. P. Science 1993, 260, 920.
  • 4Saltzman, W. M. In Principles of Tissue Engineering, Eds.:Lanza, R. P.; Langer, R.; Chick, W. L., Landes R. G. Company, Austin, 1997, p. 225.
  • 5Hench, L. L.; Polak, J. M. Science 2002, 295, 1014.
  • 6Altman, G. H.; Diaz, F.; Jakuba, C., Calabro, T.; Horan, R.L.; Chen, J.-S.; Lu, H.; Richmond, J.; Kaplan, D. L. Biomaterials 2003, 24, 401.
  • 7Li, M.-Z.; Ogiso, M.; Minoura, N. Biomaterials 2003, 24,357.
  • 8He, S.-J.; Valluzzi, R.; Gido, S. P. Int. Y. Biol. Macromol,1999, 24, 187.
  • 9Okuyama, K.; Somashekar, R.; Noguchi, K.; Ichimura, S.Biopolymers 2001, 59, 310.
  • 10Valluzzi, R.; Gido, S. P., Muller, W.; Kaplan, D. L. Int. J.Biol. Macromol. 1999, 24, 237.

共引文献10

同被引文献35

  • 1牛效迪,傅强,潘亚茹,李银燕,郝向荣,赵宝中.酞菁钴吡啶轴向配合物的合成及表征[J].分子科学学报,2005,21(3):25-28. 被引量:8
  • 2李加荣,陈博仁,欧育湘,贾会平.3-氨基-1,2,4-三唑与苦基氯的亲核取代反应动力学研究[J].北京理工大学学报,1995,15(1):34-38. 被引量:2
  • 3钮倩倩,潘利华,李珍,马世盐,谢文兵,林敏,付强.2,6-二溴-4-氨基吡啶的合成[J].分子科学学报,2006,22(6):401-404. 被引量:4
  • 4张田林,马臣华,王丽.2,6-二(4-氯甲基苯基)苯并[1,2-d;5,4-d′]二噁唑的合成[J].淮海工学院学报(自然科学版),2007,16(2):44-46. 被引量:2
  • 5Roberson E. D,Mucke L. 100 years and counting: prospects for defea- ting Alzheimer's disease[J]. Science,2006,314(5800) :781 -784.
  • 6Ropacki S. A. ,Jeste D. V. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003 [ J ]. American Journal of Psychiatry,2005,162 ( 11 ) :2022 - 2030.
  • 7Ferri C. P. , Prince M. , Brayne C. , et al. Global prevalence of demen- tia: a Delphi consensus study [ J ]. The Lancet, 2005,366 ( 9503 ) : 2112 -2117.
  • 8Lambert M. , Barlow A. , Chromy B. , et al. Diffusible, nonfibrillar lig- ands derived from Aβ1-42 are potent central nervous system neurotoxins [J]. Proceedings of the National Academy of Sciences, 1998,95 ( 11 ) : 6448 - 6453.
  • 9Ahn H. J. ,Zamolodchikov D. ,Cortes- Canteli M. , et al. Alzheimer's disease peptide β- amyloid interacts with fibrinogen and induces its oli- gomerization [ J ]. Proceedings of the National Academy of Sciences, 2010,107(50) :21812 -21817.
  • 10Findeis M. A. Peptide inhibitors of beta amyloid aggregation [ J ]. Cur- rent Topics in Medicinal Chemistry,2002,2 (4) :417 - 423.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部